Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.

Ruwaard J, Marsman AF, Nurmohamed MT, van der Horst-Bruinsma IE, Te Velthuis H, Bloem K, de Vries A, Rispens T, Wolbink G.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):756-761. Epub 2019 Mar 18.

2.

Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.

van Bezooijen JS, van Doorn MBA, Schreurs MWJ, Koch BCP, Te Velthuis H, Prens EP, van Gelder T.

Ther Drug Monit. 2017 Aug;39(4):379-386. doi: 10.1097/FTD.0000000000000420.

PMID:
28570371
3.

Measurement of free light chains with assays based on monoclonal antibodies.

Te Velthuis H, Drayson M, Campbell JP.

Clin Chem Lab Med. 2016 Jun 1;54(6):1005-14. doi: 10.1515/cclm-2015-0963. Review.

PMID:
27010775
4.

Reply to Berlanga et al. (DOI 10.1515/cclm-2014-0420).

Jacobs JF, Hoedemakers RM, te Velthuis H.

Clin Chem Lab Med. 2014 Nov;52(11):e247-8. doi: 10.1515/cclm-2014-0599. No abstract available.

PMID:
25153421
5.

N Latex FLC serum free light-chain assays in patients with renal impairment.

Jacobs JF, Hoedemakers RM, Teunissen E, Te Velthuis H.

Clin Chem Lab Med. 2014 Jun;52(6):853-9. doi: 10.1515/cclm-2013-0864.

PMID:
24406282
6.

Effect of sample dilution on two free light chain nephelometric assays.

Jacobs JF, Hoedemakers RM, Teunissen E, van der Molen RG, te Velthuis H.

Clin Chim Acta. 2012 Oct 9;413(19-20):1708-9. doi: 10.1016/j.cca.2012.04.032. Epub 2012 May 3. No abstract available.

PMID:
22588162
7.

Tissue factor pathway inhibitor is an inhibitor of factor VII-activating protease.

Stephan F, Dienava-Verdoold I, Bulder I, Wouters D, Mast AE, Te Velthuis H, Aarden LA, Zeerleder S.

J Thromb Haemost. 2012 Jun;10(6):1165-71. doi: 10.1111/j.1538-7836.2012.04712.x.

8.

Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis.

Hoedemakers RM, Pruijt JF, Hol S, Teunissen E, Martens H, Stam P, Melsert R, Te Velthuis H.

Clin Chem Lab Med. 2011 Nov 23;50(3):489-95. doi: 10.1515/CCLM.2011.793.

PMID:
22098433
9.

N Latex FLC - new monoclonal high-performance assays for the determination of free light chain kappa and lambda.

te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, Teunissen E, Fischedick KS, Althaus H, Schmidt B, Wagner C, Melsert R.

Clin Chem Lab Med. 2011 Aug;49(8):1323-32. doi: 10.1515/CCLM.2011.624. Epub 2011 Jun 10.

PMID:
21663464
10.

Label-free assessment of high-affinity antibody-antigen binding constants. Comparison of bioassay, SPR, and PEIA-ellipsometry.

Rispens T, Te Velthuis H, Hemker P, Speijer H, Hermens W, Aarden L.

J Immunol Methods. 2011 Feb 28;365(1-2):50-7. doi: 10.1016/j.jim.2010.11.010. Epub 2010 Nov 27.

PMID:
21115013
11.

Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP).

Zeerleder S, Zwart B, te Velthuis H, Stephan F, Manoe R, Rensink I, Aarden LA.

FASEB J. 2008 Dec;22(12):4077-84. doi: 10.1096/fj.08-110429. Epub 2008 Aug 27.

PMID:
18753248
12.

A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells.

Zeerleder S, Zwart B, te Velthuis H, Manoe R, Bulder I, Rensink I, Aarden LA.

FEBS Lett. 2007 Nov 27;581(28):5382-8. Epub 2007 Oct 30.

13.

Glycine does not add to the beneficial effects of perioperative oral immune-enhancing nutrition supplements in high-risk cardiac surgery patients.

Tepaske R, te Velthuis H, Oudemans-van Straaten HM, Bossuyt PM, Schultz MJ, Eijsman L, Vroom M.

JPEN J Parenter Enteral Nutr. 2007 May-Jun;31(3):173-80.

PMID:
17463141
14.

Tissue factor serum levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.

Keller TT, Choi D, Nagel C, Te Velthuis H, Gerdes VE, Wareham NJ, Bingham SA, Luben R, Hack CE, Reitsma PH, Levi M, Khaw KT, Boekholdt SM.

J Thromb Haemost. 2006 Nov;4(11):2391-6. Epub 2006 Aug 28. Erratum in: J Thromb Haemost. 2006 Dec;4(12):2742. Choi, D [added].

15.

High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation.

van der Putten RF, te Velthuis H, Aarden LA, ten Cate H, Glatz JF, Hermens WT.

Clin Chem Lab Med. 2005;43(12):1386-91.

PMID:
16309378
16.

State and diagnostic value of plasma tissue factor in early-hospitalised patients with chest pain.

van der Putten RF, te Velthuis HT, de Zwaan C, Aarden LA, Glatz JF, Hermens WT.

Br J Haematol. 2005 Oct;131(1):91-9.

PMID:
16173968
17.

Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells.

de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT.

Clin Diagn Lab Immunol. 2003 Jan;10(1):133-9.

18.

The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.

Bos IG, van Mierlo GJ, Bleeker WK, Rigter GM, te Velthuis H, Dickneite G, Hack CE.

Int Immunopharmacol. 2001 Aug;1(8):1583-95.

PMID:
11515821
19.

Comparison of three commercially available hollow fiber oxygenators: gas transfer performance and biocompatibility.

de Vroege R, Wagemakers M, te Velthuis H, Bulder E, Paulus R, Huybregts R, Wildevuur W, Eijsman L, van Oeveren W, Wildevuur C.

ASAIO J. 2001 Jan-Feb;47(1):37-44.

PMID:
11199313
20.
21.

Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro.

Bruins P, te Velthuis H, Eerenberg-Belmer AJ, Yazdanbakhsh AP, de Beaumont EM, Eijsman L, Trouwborst A, Hack CE.

Thromb Haemost. 2000 Aug;84(2):237-43.

PMID:
10959695
22.

Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps.

Baufreton C, Intrator L, Jansen PG, te Velthuis H, Le Besnerais P, Vonk A, Farcet JP, Wildevuur CR, Loisance DY.

Ann Thorac Surg. 1999 Apr;67(4):972-7.

PMID:
10320237
23.

Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits.

Baufreton C, Moczar M, Intrator L, Jansen PG, te Velthuis H, Le Besnerais P, Farcet JP, Wildevuur CR, Loisance DY.

Perfusion. 1998 Nov;13(6):419-27.

PMID:
9881389
24.

Biphasic release of secretory phospholipase A2 during and after cardiopulmonary bypass.

Bruins P, te Velthuis H, Jansen PG, Eijsman L, Hack CE.

J Thorac Cardiovasc Surg. 1998 Apr;115(4):949-51. No abstract available.

25.

Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia.

Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, Hack CE.

Circulation. 1997 Nov 18;96(10):3542-8.

PMID:
9396453
26.

Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma.

Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE.

J Immunol. 1997 Aug 15;159(4):1953-60.

PMID:
9257861
27.

Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations.

te Velthuis H, Baufreton C, Jansen PG, Thijs CM, Hack CE, Sturk A, Wildevuur CR, Loisance DY.

J Thorac Cardiovasc Surg. 1997 Jul;114(1):117-22.

28.

Heparin coating with aprotinin reduces blood activation during coronary artery operations.

Baufreton C, Jansen PG, Le Besnerais P, te Velthuis H, Thijs CM, Wildevuur CR, Loisance DY.

Ann Thorac Surg. 1997 Jan;63(1):50-6.

PMID:
8993240
29.

Increased oxygen consumption after cardiac surgery is associated with the inflammatory response to endotoxemia.

Oudemans-van Straaten HM, Jansen PG, te Velthuis H, Beenakkers IC, Stoutenbeek CP, van Deventer SJ, Sturk A, Eysman L, Wildevuur CR.

Intensive Care Med. 1996 Apr;22(4):294-300.

PMID:
8708165
30.

Specific complement inhibition with heparin-coated extracorporeal circuits.

te Velthuis H, Jansen PG, Hack CE, Eijsman L, Wildevuur CR.

Ann Thorac Surg. 1996 Apr;61(4):1153-7.

PMID:
8607674
31.

Circulating endothelin in cardiac operations: influence of blood pressure and endotoxin.

te Velthuis H, Jansen PG, Oudemans-van Straaten HM, van Kamp GJ, Sturk A, Eijsman L, Wildevuur CR.

Ann Thorac Surg. 1996 Mar;61(3):904-8.

PMID:
8619715
32.

Cardiopulmonary bypass with modified fluid gelatin and heparin-coated circuits.

Jansen PG, te Velthuis H, Wildevuur WR, Huybregts MA, Bulder ER, van der Spoel HI, Sturk A, Eijsman L, Wildevuur CR.

Br J Anaesth. 1996 Jan;76(1):13-9.

33.

Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor.

te Velthuis H, Jansen PG, Oudemans-van Straaten HM, Sturk A, Eijsman L, Wildevuur CR.

J Thorac Cardiovasc Surg. 1995 Dec;110(6):1663-9.

34.

Reduction in prime volume attenuates the hyperdynamic response after cardiopulmonary bypass.

Jansen PG, te Velthuis H, Bulder ER, Paulus R, Scheltinga MR, Eijsman L, Wildevuur CR.

Ann Thorac Surg. 1995 Sep;60(3):544-9; discussion 549-50.

PMID:
7677478
35.

Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits.

Jansen PG, te Velthuis H, Huybregts RA, Paulus R, Bulder ER, van der Spoel HI, Bezemer PD, Slaats EH, Eijsman L, Wildevuur CR.

J Thorac Cardiovasc Surg. 1995 Sep;110(3):829-34.

36.

Perfusion-related factors of endotoxin release during cardiopulmonary bypass.

Jansen PG, Te Velthuis H, Oudemans-Van Straaten HM, Bulder ER, Van Deventer SJ, Sturk A, Eijsman L, Wildevuur CR.

Eur J Cardiothorac Surg. 1994;8(3):125-9.

PMID:
8011344

Supplemental Content

Loading ...
Support Center